Clinical Trial Update: Safety Study of Tezepelumab (AMG 157) in Healthy Adults and Adults With Atopic Dermatitis [Phase 1]

View source ↗

Summary

Phase 1 safety trial of tezepelumab (AMG 157) in healthy adults and adults with atopic dermatitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Tezepelumab (tezepelumab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis, Healthy Volunteers | Phase 1 | Status: COMPLETED | Results posted: 2022-07-18